دورية أكاديمية
أعرض في EDS

Changes of Protein Expression after CRISPR/Cas9 Knockout of miRNA-142 in Cell Lines Derived from Diffuse Large B-Cell Lymphoma.

التفاصيل البيبلوغرافية
العنوان: Changes of Protein Expression after CRISPR/Cas9 Knockout of miRNA-142 in Cell Lines Derived from Diffuse Large B-Cell Lymphoma.
المؤلفون: Menegatti J; Institute of Virology, Saarland University Medical School, 66421 Homburg, Germany., Nakel J; Institute of Virology, Saarland University Medical School, 66421 Homburg, Germany., Stepanov YK; Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, Ludwig-Maximilians-University Munich, 81377 Munich, Germany., Caban KM; Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, Ludwig-Maximilians-University Munich, 81377 Munich, Germany., Ludwig N; Institute of Human Genetics, Saarland University, 66421 Homburg, Germany., Nord R; Institute of Virology, Saarland University Medical School, 66421 Homburg, Germany., Pfitzner T; Institute of Virology, Saarland University Medical School, 66421 Homburg, Germany., Yazdani M; Institute of Virology, Saarland University Medical School, 66421 Homburg, Germany., Vilimova M; Institute of Virology, Saarland University Medical School, 66421 Homburg, Germany., Kehl T; Center for Bioinformatics, Saarland University, 66041 Saarbrücken, Germany., Lenhof HP; Center for Bioinformatics, Saarland University, 66041 Saarbrücken, Germany., Philipp SE; Experimental and Clinical Pharmacology and Toxicology, Saarland University Medical School, 66421 Homburg, Germany., Meese E; Institute of Human Genetics, Saarland University, 66421 Homburg, Germany., Fröhlich T; Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, Ludwig-Maximilians-University Munich, 81377 Munich, Germany., Grässer FA; Institute of Virology, Saarland University Medical School, 66421 Homburg, Germany., Hart M; Institute of Human Genetics, Saarland University, 66421 Homburg, Germany.
المصدر: Cancers [Cancers (Basel)] 2022 Oct 14; Vol. 14 (20). Date of Electronic Publication: 2022 Oct 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Background: As microRNA-142 (miR-142) is the only human microRNA gene where mutations have consistently been found in about 20% of all cases of diffuse large B-cell lymphoma (DLBCL), we wanted to determine the impact of miR-142 inactivation on protein expression of DLBCL cell lines.
Methods: miR-142 was deleted by CRISPR/Cas9 knockout in cell lines from DLBCL.
Results: By proteome analyses, miR-142 knockout resulted in a consistent up-regulation of 52 but also down-regulation of 41 proteins in GC-DLBCL lines BJAB and SUDHL4. Various mitochondrial ribosomal proteins were up-regulated in line with their pro-tumorigenic properties, while proteins necessary for MHC-I presentation were down-regulated in accordance with the finding that miR-142 knockout mice have a defective immune response. CFL2, CLIC4, STAU1, and TWF1 are known targets of miR-142, and we could additionally confirm AKT1S1, CCNB1, LIMA1, and TFRC as new targets of miR-142-3p or -5p.
Conclusions: Seed-sequence mutants of miR-142 confirmed potential targets and novel targets of miRNAs can be identified in miRNA knockout cell lines. Due to the complex contribution of miRNAs within cellular regulatory networks, in particular when miRNAs highly present in RISC complexes are replaced by other miRNAs, primary effects on gene expression may be covered by secondary layers of regulation.
References: Nat Commun. 2018 May 10;9(1):1860. (PMID: 29749375)
Cell Death Differ. 2021 Feb;28(2):715-729. (PMID: 32929219)
FEBS Open Bio. 2016 Feb 27;6(4):251-63. (PMID: 27239439)
Eur J Immunol. 2017 Jul;47(7):1142-1152. (PMID: 28471480)
Cell Physiol Biochem. 2018;50(6):2097-2107. (PMID: 30415244)
Oncotarget. 2016 Jun 7;7(23):34288-99. (PMID: 27144431)
Noncoding RNA. 2015 Sep 30;1(3):170-191. (PMID: 29861423)
J Biol Chem. 2012 Oct 26;287(44):36663-72. (PMID: 22961981)
Mol Cell Biol. 2006 Mar;26(6):2373-86. (PMID: 16508012)
Cell Death Differ. 2010 Feb;17(2):193-9. (PMID: 19461653)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Eur J Haematol. 2017 Jan;98(1):52-56. (PMID: 27301795)
Aging (Albany NY). 2020 Apr 23;12(8):7380-7396. (PMID: 32327611)
J Cell Physiol. 2019 Jun;234(6):9816-9825. (PMID: 30480817)
J Clin Lab Anal. 2021 Aug;35(8):e23793. (PMID: 34196992)
Nat Protoc. 2009;4(1):44-57. (PMID: 19131956)
Front Genet. 2021 Mar 17;12:637887. (PMID: 33815471)
Blood. 2019 May 30;133(22):2401-2412. (PMID: 30975638)
Anal Biochem. 1976 May 7;72:248-54. (PMID: 942051)
J Immunol. 2008 Nov 1;181(9):5963-73. (PMID: 18941185)
Cancer Lett. 2013 Jan 28;328(2):198-206. (PMID: 23022474)
Leukemia. 2017 Jan;31(1):83-91. (PMID: 27389057)
Nature. 2021 Jan;589(7841):299-305. (PMID: 33299181)
Mol Cancer. 2006 Jul 19;5:29. (PMID: 16854228)
Proc Natl Acad Sci U S A. 1989 Nov;86(22):8867-71. (PMID: 2682663)
RNA Biol. 2018 Feb 1;15(2):242-250. (PMID: 29219730)
Nucleic Acids Res. 2022 Mar 23;:. (PMID: 35325185)
Hum Pathol. 2014 Oct;45(10):2115-9. (PMID: 25130394)
Nature. 2013 Mar 7;495(7439):50-1. (PMID: 23467164)
Oncotarget. 2017 Sep 21;8(54):92209-92226. (PMID: 29190909)
Mol Neurobiol. 2020 Jul;57(7):2996-3013. (PMID: 32451872)
Nat Biotechnol. 2008 Dec;26(12):1367-72. (PMID: 19029910)
Cardiovasc Res. 2017 Apr 01;113(5):440-452. (PMID: 28073833)
Nat Commun. 2016 Oct 24;7:13166. (PMID: 27774986)
Cell Rep. 2022 Jan 25;38(4):110227. (PMID: 35081338)
Trends Mol Med. 2014 Aug;20(8):460-9. (PMID: 25027972)
Int J Mol Sci. 2020 Nov 23;21(22):. (PMID: 33238645)
Cancer Res. 2017 May 1;77(9):2328-2338. (PMID: 28202517)
Br J Cancer. 2019 Apr;120(7):703-713. (PMID: 30804430)
Oncogene. 2007 Jul 26;26(34):5017-22. (PMID: 17297439)
Cancers (Basel). 2019 Jun 08;11(6):. (PMID: 31181801)
Cell Physiol Biochem. 2017;43(6):2505-2515. (PMID: 29131028)
Nat Rev Cancer. 2018 Jan;18(1):5-18. (PMID: 29170536)
Haematologica. 2016 Nov;101(11):1380-1389. (PMID: 27390358)
Thorax. 2020 Oct;75(10):870-881. (PMID: 32759383)
Blood. 2015 Jun 11;125(24):3720-30. (PMID: 25931583)
Mol Diagn Ther. 2016 Dec;20(6):509-518. (PMID: 27378479)
Mol Cancer Res. 2005 Dec;3(12):645-53. (PMID: 16380502)
Nat Cell Biol. 2019 Sep;21(9):1093-1101. (PMID: 31451768)
Biol Chem. 2014 Jun;395(6):611-29. (PMID: 24603840)
Immunity. 2019 Sep 17;51(3):479-490.e6. (PMID: 31402259)
Neoplasma. 2013;60(4):432-8. (PMID: 23581416)
Semin Cancer Biol. 2021 Jun 1;:. (PMID: 34087417)
Nucleic Acids Res. 2014 Apr;42(7):4629-39. (PMID: 24464996)
Cell Biol Int. 2020 Nov;44(11):2334-2343. (PMID: 32776663)
Immunogenetics. 2019 Mar;71(3):251-261. (PMID: 30675634)
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613. (PMID: 30476243)
Cell. 2009 Jan 23;136(2):215-33. (PMID: 19167326)
Elife. 2014 May 23;3:e01964. (PMID: 24859754)
Front Oncol. 2019 Dec 13;9:1373. (PMID: 31921637)
J Cancer. 2020 Jan 14;11(6):1614-1624. (PMID: 32047567)
Clin Cancer Res. 2016 Nov 1;22(21):5189-5195. (PMID: 27582489)
Methods Mol Biol. 2011;732:153-67. (PMID: 21431712)
Blood. 2010 Dec 9;116(24):5316-26. (PMID: 20876853)
Cancer Med. 2012 Oct;1(2):141-55. (PMID: 23342264)
Oncogene. 2021 Mar;40(10):1775-1791. (PMID: 33564074)
RNA Biol. 2007 Jun;4(2):76-84. (PMID: 17637574)
Blood. 2011 May 12;117(19):5019-32. (PMID: 21300984)
PLoS One. 2015 Sep 01;10(9):e0136913. (PMID: 26327117)
Mol Cell Endocrinol. 2019 Aug 20;494:110489. (PMID: 31202817)
Adv Biol Regul. 2015 Jan;57:1-9. (PMID: 25294678)
Nucleic Acids Res. 2020 Oct 9;48(18):10164-10183. (PMID: 32990751)
Nature. 2019 Aug;572(7769):402-406. (PMID: 31341276)
Ann Oncol. 2011 Oct;22(10):2257-66. (PMID: 21343377)
FEBS J. 2013 May;280(9):2105-16. (PMID: 23480797)
Cancer Res. 2018 Jul 1;78(13):3510-3521. (PMID: 29724719)
J Virol. 2019 Jan 17;93(3):. (PMID: 30429351)
Cell Metab. 2019 Feb 5;29(2):348-361.e6. (PMID: 30318337)
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552. (PMID: 34723319)
Nature. 2015 Sep 3;525(7567):124-8. (PMID: 26214738)
Int J Oncol. 2013 May;42(5):1569-77. (PMID: 23545944)
Nat Methods. 2016 Sep;13(9):731-40. (PMID: 27348712)
Carcinogenesis. 2017 May 1;38(5):485-491. (PMID: 28449079)
Mol Cancer. 2018 Jan 24;17(1):13. (PMID: 29368606)
Curr Mol Med. 2018;18(3):135-141. (PMID: 30198432)
Nat Rev Cancer. 2006 Nov;6(11):857-66. (PMID: 17060945)
Nat Commun. 2015 Jan 08;6:5908. (PMID: 25569716)
JCI Insight. 2020 May 7;5(9):. (PMID: 32376798)
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9. (PMID: 16641092)
Nucleic Acids Res. 2011 Mar;39(5):1880-93. (PMID: 21062812)
Mol Cell Proteomics. 2012 May;11(5):77-89. (PMID: 22442255)
EMBO J. 2007 Mar 21;26(6):1624-36. (PMID: 17332740)
Oncotarget. 2016 Feb 23;7(8):9163-74. (PMID: 26824321)
Mol Cell. 2009 Nov 25;36(4):631-41. (PMID: 19941823)
Clin Cancer Res. 2016 May 1;22(9):2290-300. (PMID: 26647218)
فهرسة مساهمة: Keywords: AKT1S1; CCNB1; CRISPR/Cas9; LIMA1; TFRC; diffuse large B-cell lymphoma; miR-142 knockout cell lines; microRNA-142; proteomics; transcriptomics
تواريخ الأحداث: Date Created: 20221027 Latest Revision: 20221030
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9600116
DOI: 10.3390/cancers14205031
PMID: 36291816
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers14205031